Literature DB >> 14768004

Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome.

Sarwa Darwish Murad1, Dominique-Charles Valla, Piet C de Groen, Guy Zeitoun, Judith A M Hopmans, Elizabeth B Haagsma, Bart van Hoek, Bettina E Hansen, Frits R Rosendaal, Harry L A Janssen.   

Abstract

Budd-Chiari syndrome (BCS) is a rare disorder that is characterized by hepatic venous outflow obstruction. The aim of this study was to assess determinants of survival and to evaluate the effect of portosystemic shunting. In this international multicenter study, 237 patients with BCS, diagnosed between 1984 and 2001, were investigated. Univariate, multivariate, and time-dependent Cox regression analyses were performed. Overall survival at 1, 5, and 10 years was 82% (95% CI, 77%-87%), 69% (95% CI, 62%-76%), and 62% (95% CI, 54%-70%), respectively. Encephalopathy, ascites, prothrombin time, and bilirubin were independent determinants of survival. A prognostic classification combining these factors could identify three classes of patients (classes I-III). The 5-year survival rate was 89% (95% CI, 79%-99%) for class I, 74% (95% CI, 65%-83%) for class II, and 42% (95% CI, 28%-56%) for class III. Anticoagulants were administered to 72%; only for patients in class I was this associated with a trend toward improved survival (relative risk [RR], 0.14; 95% CI, 0.02-1.21). Portosystemic shunting was performed in 49% of the patients (n = 117); only for patients in class II, time-dependent analyses suggested an improved survival (RR, 0.63; 95% CI, 0.26-1.49). In conclusion, at the time of diagnosis, patients with BCS can be classified into good (I), intermediate (II), and poor (III) prognostic classes, according to simple baseline clinical and laboratory parameters. Our results suggest an improved survival after surgical portosystemic shunting for patients with an intermediate prognosis (class II).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14768004     DOI: 10.1002/hep.20064

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  61 in total

Review 1.  Splanchnic vein thrombosis: clinical presentation, risk factors and treatment.

Authors:  Valerio De Stefano; Ida Martinelli
Journal:  Intern Emerg Med       Date:  2010-06-08       Impact factor: 3.397

2.  Budd-Chiari syndrome: outcomes of endovascular intervention-A single-center experience.

Authors:  Nitin Jagtap; Mithun Sharma; Jagdeesh Singh; Manu Tandan; P N Rao; Rajesh Gupta; Sundeep Lakhtakia; Mohan Ramchandani; Harshal Shah; T Mahesh Kumar; Santosh Darishetty; G V Rao; D N Reddy
Journal:  Indian J Gastroenterol       Date:  2017-06-20

3.  Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome.

Authors:  C E Eapen; D Velissaris; M Heydtmann; B Gunson; S Olliff; E Elias
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

4.  Prognosis in Budd Chiari syndrome after re-establishing hepatic venous drainage.

Authors:  D-C Valla
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

5.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

6.  Aetiological factors of Budd-Chiari syndrome in Algeria.

Authors:  Nawel Afredj; Nawal Guessab; Abdelbasset Nani; Sid Ahmed Faraoun; Ibtissem Ouled Cheikh; Rafik Kerbouche; Djouhar Hannoun; Zine Charef Amir; Hayet Ait Kaci; Kamel Bentabak; Aurélie Plessier; Dominique-Charles Valla; Valerie Cazals-Hatem; Marie-Hélène Denninger; Tadjeddine Boucekkine; Nabil Debzi
Journal:  World J Hepatol       Date:  2015-04-28

Review 7.  Liver cirrhosis in hepatic vena cava syndrome (or membranous obstruction of inferior vena cava).

Authors:  Santosh Man Shrestha
Journal:  World J Hepatol       Date:  2015-04-28

8.  Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction.

Authors:  Praveer Rai; Pankaj Kumar; Swapnil Mishra; Rakesh Aggarwal
Journal:  Indian J Gastroenterol       Date:  2016-09-16

9.  Budd-Chiari syndrome associated with visceral leishmaniasis and factor V Leiden mutation.

Authors:  Emel Gürkan; Cağatay Unsal; Fikri Başlamişli; Didem Arslan
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

10.  Endovascular stenting of the inferior vena cava in a patient with Budd-Chiari syndrome and main hepatic vein thrombosis: a case report.

Authors:  Young-In Yoon; Shin Hwang; Gi-Young Ko; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Young-Sang Lee; Sung-Gyu Lee
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2015-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.